Literature DB >> 21266593

The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver.

Shogo J Miyagi1, Abby C Collier.   

Abstract

UDP-glucuronosyltransferases (UGTs) are critical for the metabolism and clearance of drugs, chemicals, and hormones. The development of UGT1A1 and 1A6 was studied in 50 pediatric liver samples using bilirubin, serotonin activity assays, and Western blot as well as pharmacokinetic scaling. UGT activity developed age dependently in pediatric liver. Maximal activity of 0.7690 nmol · min · (-1) mg protein(-1) was observed for UGT1A1 at 3.8 months. For UGT1A6, activity matured at 14 months (4.737 nmol · min · (-1)mg protein(-1)). Protein expression was not age-dependent, and activities did not correlate to protein levels for either enzyme. The in vitro activities were used to calculate normalized hepatic clearances using both allometric scaling and a physiologically based pharmacokinetic model. For UGT1A1, allometry predicted normalized adult clearances of 0.0070 l · h(-1) · kg(-1) at 3.0 (well stirred) and 2.8 years (parallel tube), whereas the Simcyp model showed normalized clearances of 0.0079 l · h(-1) · kg(-1) at 2.6 (well stirred) and 2.5 years (parallel tube). For UGT1A6, only the Simcyp well stirred model converged at 0.3524 l · h(-1) · kg(-1) at 12.6 months. These data imply independent regulation of UGT1A1 and 1A6 where activity has matured after 6 months to 1 year. Total hepatic clearance of substances mediated by these enzymes may mature concurrently or take longer because of other physiological factors. Late development of UGT enzymes may contribute to chemical, drug, and environmental toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266593      PMCID: PMC3082376          DOI: 10.1124/dmd.110.037192

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

Review 1.  Structural and functional studies of UDP-glucuronosyltransferases.

Authors:  A Radominska-Pandya; P J Czernik; J M Little; E Battaglia; P I Mackenzie
Journal:  Drug Metab Rev       Date:  1999-11       Impact factor: 4.518

2.  Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain.

Authors:  K Richard; R Hume; E Kaptein; E L Stanley; T J Visser; M W Coughtrie
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

3.  N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes.

Authors:  O Barbier; C Girard; R Breton; A Bélanger; D W Hum
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

Review 4.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 6.  Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.

Authors:  P Impicciatore; I Choonara; A Clarkson; D Provasi; C Pandolfini; M Bonati
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 7.  Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.

Authors:  B Burchell; M Soars; G Monaghan; A Cassidy; D Smith; B Ethell
Journal:  Toxicol Lett       Date:  2000-03-15       Impact factor: 4.372

8.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

9.  UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.

Authors:  Abby C Collier; Natalie A Ganley; Malcolm D Tingle; Marion Blumenstein; Keith W Marvin; James W Paxton; Murray D Mitchell; Jeffrey A Keelan
Journal:  Biochem Pharmacol       Date:  2002-02-01       Impact factor: 5.858

Review 10.  New concepts in bilirubin encephalopathy.

Authors:  J D Ostrow; L Pascolo; S M Shapiro; C Tiribelli
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

View more
  32 in total

1.  Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study.

Authors:  Matthew W Linakis; Sarah F Cook; Shaun S Kumar; Xiaoxi Liu; Diana G Wilkins; Roger Gaedigk; Andrea Gaedigk; Catherine M T Sherwin; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

2.  Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.

Authors:  J B Pain; M P Lê; M Caseris; C Amiel; L Lassel; C Charpentier; A Desnoyer; C Farnoux; G Pialoux; D Descamps; G Peytavin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.

Authors:  Ya-Li Nie; Hang He; Jiang-Feng Li; Xiang-Guang Meng; Liang Yan; Pei Wang; Shu-Jie Wang; Hong-Zheng Bi; Li-Rong Zhang; Quan-Cheng Kan
Journal:  Eur J Clin Pharmacol       Date:  2016-10-05       Impact factor: 2.953

4.  Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

Authors:  Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

5.  Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.

Authors:  Luc Ra Rougée; Shogo J Miyagi; Abby C Collier
Journal:  Hawaii J Med Public Health       Date:  2016-12

6.  Isoform-specific therapeutic control of sulfonation in humans.

Authors:  Ian Cook; Ting Wang; Thomas S Leyh
Journal:  Biochem Pharmacol       Date:  2018-11-10       Impact factor: 5.858

7.  Upregulation of Ugt1a genes in placentas and fetal livers in a murine model of assisted reproduction.

Authors:  A C Collier; K A Milam; L R A Rougée; A Sugawara; Y Yamauchi; M A Ward
Journal:  Placenta       Date:  2011-11-25       Impact factor: 3.481

Review 8.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

9.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

10.  Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Authors:  Joshua Gini; Sujan Dilly Penchala; Alieu Amara; Elizabeth Challenger; Deirdre Egan; Catriona Waitt; Mohammed Lamorde; Catherine Orrell; Landon Myer; Saye Khoo; Laura J Else
Journal:  Bioanalysis       Date:  2018-11-19       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.